SCHEMBL6769208

SCHEMBL6769208

Cc1ccc(NC(=O)Nc2ccc(S(=O)(=O)CC(C)(O)C(=O)NO)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
PTPN7 P35236 1/20 0.52
GHSR Q92847 1/20 0.48
PKM P14618 2/20 0.47
CYP2C9 P11712 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA9 Q16790 3/20 0.46
LMNA P02545 1/20 0.45
ALOX12 P18054 1/20 0.45
IDO1 P14902 1/20 0.45
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6767619 0.90 CYP2C19 (0.55) ALDH1A1MEN1KMT2AGHSRCYP2C9
SCHEMBL6769180 0.88 GHSR (0.53) ALDH1A1MEN1KMT2AGHSRPKM
SCHEMBL6768584 0.86 GHSR (0.53) ALDH1A1MEN1KMT2AGHSRCYP2C9
SCHEMBL7074011 0.82 AR (0.62) ALDH1A1MEN1KMT2AGHSRCYP2C9
SCHEMBL6764598 0.81 PTPN1 (0.51) ALDH1A1CYP2C9CYP3A4CYP2D6CYP2C19
SCHEMBL6764633 0.80 NPC1 (0.52) ALDH1A1MEN1KMT2ACYP2C9CYP3A4
SCHEMBL6764639 0.80 PRMT1 (0.55) ALDH1A1MEN1KMT2ACYP2C9CYP3A4
SCHEMBL6766794 0.79 MMP2 (0.49) ALDH1A1MEN1KMT2ACYP2C9CYP3A4
SCHEMBL6764641 0.78 MAPT (0.54) MEN1KMT2ACYP2C9CYP3A4CYP2D6
SCHEMBL2615510 0.76 AR (0.55) ALDH1A1GHSRCYP2C9CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716844-B2 ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS PHARMACIA CORPORATION 2004-04-06 US disclosed
EP-0984959-B1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2003-09-24 EP disclosed
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds PHARMACIA CORPORATION 2002-11-21 US disclosed
US-6362183-B1 PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS G. D. SEARLE & COMPANY 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds MMP1, MMP2, MMP3 ALDH1A1 593/4885MEN1 3814/4885KMT2A 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.